

Case Report

An unusual case of primary peritoneal adenocarcinoma

**Rajdave Singh Sadu Singh*, Muhammad Rahimi Mohamad Hisham,
Ahmad Tarmizi Mohammad, Shabbar Husain Fazle Abbas, Yussra Yusoff**

Department of General Surgery, Hospital Angkatan Tentera Tuanku Mizan, Kuala Lumpur, Malaysia

Received: 21 August 2020

Accepted: 14 September 2020

***Correspondence:**

Dr. Rajdave Singh Sadu Singh,
E-mail: rajdavee.s@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Primary peritoneal adenocarcinoma is sporadic with few cases cited in pre-existing literature. This cancer arises from the peritoneal epithelium lining of the abdomen, which is derived from extra ovarian mesothelium. It generally carries a poor prognosis. The treatment strategies are similar to ovarian serous papillary carcinoma. Report an incidental finding of primary peritoneal adenocarcinoma in a 39-year-old female army personnel, currently undergoing her chemotherapy and thriving. Exploratory laparotomy was done given the incidental finding of a mass on the contrast-enhanced computed tomography scan (CT). The mass was attached to the greater omentum, however, did not invade the mucosa of the transverse colon. Given this, part of greater omentum was removed. The findings of the immunohistochemical studies of the tumour are described within this report. The diagnosis of a primary peritoneal adenocarcinoma, stage II was established as no other primary site were found upon further investigation. The patient was treated with chemotherapy (carboplatin/paclitaxel) which was planned for 6 cycles. Otherwise, the patient had an uneventful postoperative course, is underway her chemotherapy regime and is planned for interim CT study to assess chemotherapy response. To conclude, isolated solitary primary peritoneal adenocarcinoma without peritoneal carcinomatosis, gastrointestinal manifestations and ascites are rare. This case, however, demonstrates the importance of its diagnosis, accurate evaluation and management.

Keywords: Peritoneal carcinoma, Adenocarcinoma, Omental tumor

INTRODUCTION

Primary peritoneal adenocarcinoma is sporadic with only a few cases cited in pre-existing literature.¹ This type of cancer arises from the peritoneal epithelium lining of the abdominal and pelvic cavities, which is characterized by intraperitoneal carcinomatosis involving the peritoneum and omentum. For the most part, it occurs in menopausal or post-menopausal women. The incidence rate of primary peritoneal carcinoma was reported at 6.78 per 1000,000 individuals in the United States.² It carries a poor prognosis with a mean survival rate of 5 years at 40% of the recorded cases. Histologically it is similar to an ovarian tumour due to the embryonic origin of the peritoneum.³ This tumour typically presents with abdominal discomfort, distension, other gastrointestinal

complaints and less commonly a discernible mass. Present a unique case of a 39-year-old patient, who initially presented with symptoms mimicking pulmonary tuberculosis with the absence of gastrointestinal manifestations. She was later diagnosed with primary peritoneal adenocarcinoma.

CASE REPORT

A 39-year-old woman presented to her city health services in February 2020 with a history of dry cough, unintentional weight loss of 14 kg over two months, loss of appetite and occasional fever. Subsequently, she was referred to centre for further evaluation. Upon additional history taking, she denied any altered bowel habits, acid reflux, haematemesis, nausea, nor vomiting. Physical

examination on admission was unremarkable. The patient was then worked up for tuberculosis due to the suggestive history. Mantoux test showed 15mm induration however other laboratory investigations such as sputum acid-fast bacilli, erythrocyte sedimentation rate (ESR), MTB PCR and bronchoalveolar lavage yielded negative results. Carcinoembryonic antigen, cancer antigen 125 and cancer antigen 19-9 studies were within the normal range.

On day 2 of admission, the patient developed a high-grade temperature, and she was thereafter started on intravenous Tazobactam and Ceftriaxone. Due to inadequate response to the antibiotic regime, a contrast enhanced CT Thorax, Abdomen and Pelvis was done in hopes to locate the foci of infection. The CT study revealed a broad left-sided soft tissue mass measuring approximately 6.4×5.5×6.3 cm with tortuous surrounding vessels (Figure 1). The aforementioned lesion was in close contact with the bowel displacing it medially. Based on these findings, an exploratory laparotomy was done for the patient and revealed a large mass attached to the greater omentum that did not invade the mucosa of the transverse colon. Subsequently, part of greater omentum was removed. Histopathological examination of this mass revealed poorly differentiated adenocarcinoma of the omentum. Immunoprofiling suggested either primary peritoneal carcinoma or metastasis from the following primary areas, i.e., thyroid, salivary glands, breast, lung and ovary. This patient was then sent for a positron emission tomography (PET) CT which confirmed the diagnosis of primary peritoneal adenocarcinoma, stage II.⁴ The PET CT (Figure 3) had no significant finding, no hypermetabolic activity at the previous surgical site likely keeping with complete excision of tumour. Thereafter, the patient was treated with chemotherapy (carboplatin/paclitaxel) which was initiated in May 2020 planned for 6 cycles the patient otherwise has had an uneventful postoperative course and is underway her chemotherapy regime.




Figure 1: Contrast enhanced CT abdomen coronal view.



Figure 2: Omental mass at greater omentum.



Figure 3: PET scan shows no evidence of a fluorodeoxyglucose avid lesion to suggest a primary site of disease.

DISCUSSION

Primary peritoneal adenocarcinoma tumour is a rare malignancy which arises from extra ovarian mesothelial cells with Mullerian potential. Different nomenclatures have been used including serous surface papillary carcinoma, primary peritoneal papillary serous adenocarcinoma, serous surface carcinoma of the peritoneum, extra ovarian peritoneal serous papillary carcinoma, papillary serous carcinoma of the peritoneum and peritoneal papillary carcinoma. This malignancy was first reported in 1959 by Swerdlow et al.⁵⁻¹⁰

The most common presenting symptoms of PPAC are abdominal distension, abdominal pain and reduced appetite; however, in this case, this particular patient lacked gastrointestinal related symptoms. It occurs almost exclusively to menopausal and post-menopausal women; however, a case of primary peritoneal adenocarcinoma in a male was reported by Shmeuli et al.¹¹ In this case is unique in its presentation of atypical clinical features, an isolated omental mass without a peritoneal spread and not being within the usually reported age group.

Radiological imaging has proven to be a valuable tool in diagnosing and guiding surgical management. The patients, contrast-enhanced CT was the primary modality that aided us in diagnosing this patient, whereas the PET CT played a vital role in defining the extent of the underlying malignancy and its ability to detect distant metastasis.

In postoperative immuno-histological examinations, PPAC is typically positive for cytokeratin-7, CA-125 oestrogens receptor and Wilms tumour -1 (WT-1). In the current case, only cytokeratin -7 was positive. However, it was not tested for Wilm's tumour.

Patients with primary peritoneal adenocarcinoma ideally should be treated with cytoreductive surgery followed by chemo regime similar to ovarian serous peritoneal carcinoma (OSPC). Platinum-based combination chemotherapy identical to ovarian cancer is widely recommended. Ayhan et al reported 32 PSPC and 43 OSPC patients who received adjuvant chemotherapy, carboplatin and paclitaxel after cytoreductive surgery.¹² No significant difference was noted concerning clinical or surgical response. Another clinical trial of platin based chemotherapy for 33 patients by David T et al noted the median survival time for all patients was 17 months, and three patients were alive 6 to 7 years after diagnosis was established.¹³ The patient was treated with chemotherapy (carboplatin/paclitaxel) which was planned for 6 cycles. Otherwise, the patient had an uneventful postoperative course, is underway her chemotherapy regime and is planned for interim CT study to assess chemotherapy response.

CONCLUSION

An isolated solitary primary peritoneal adenocarcinoma without peritoneal carcinomatosis, ascites and gastrointestinal symptoms are extremely rare. This case demonstrates the importance of its diagnosis, accurate evaluation and management for a favourable outcome.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

- Jordan SJ, Green AC, Whiteman DC, Moore SP, Bain CJ, Gertig DM et al. Serous ovarian, fallopian tube and primary peritoneal cancers: A comparative epidemiological analysis. *Int J Cancer.* 2008;122(7):1598-603.
- Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004. *Cancer Epidemiol Biomarkers Prev.* 2009;18(1):132-9.
- Nicolas G, Kfoury T, Fawaz H, Issa M. Extraovarian primary peritoneal carcinomatosis: A case report. *Am J Case Rep.* 2017;18:714-8.
- Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. *Arch Gynecol Obstet.* 2014;290(5):839-42.
- Gooneratne S, Sassone M, Blaustein A, Talerman A. Serous surface papillary carcinoma of the ovary: a clinicopathologic study of 16 cases. *Int J Gynecol Pathol.* 1982;1(3):258-69.
- Altaras MM, Aviram R, Cohen I, Cordoba M, Weiss E, Beyth Y. Primary peritoneal papillary serous adenocarcinoma: Clinical and management aspects. *Gynecol Oncol.* 1990;40(3):230-6.
- Truong LD, Maccato ML, Awalt H, Cagle PT, Schwartz MR, Kaplan AL. Serous surface carcinoma of the peritoneum: A clinicopathologic study of 22 cases. *Hum Pathol.* 1990;21(1):99-110.
- Alok AK, O'Reilly AP. Extraovarian peritoneal serous papillary carcinoma: Case report. *Eur J Gynaecol Oncol.* 1998;19(4):347-9.
- Lele SB, Piver MS, Matharu J, Tsukada Y. Peritoneal papillary carcinoma. *Gynecol Oncol.* 1988;31(2):315-20.
- Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary. Case report. *Am J Obstet Gynecol.* 1959;77(1):197-200.
- Shmeuli E, Leider-Trejo L, Schwartz I, Aderka D, Inbar M. Primary papillary serous carcinoma of the peritoneum in a man. *Ann Oncol.* 2001;12(4):563-7.
- Ayhan A, Taskiran C, Yigit-Celik N, Bozdog G, Gultekin M, Usulutun A et al. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for

ovarian serous papillary cancer? *Int J Gynecol Cancer*. 2006;16(2):484-9.

13. Ransom DT, Shreyaskumar R, Patel M, Gary L, Keeney George D, Malkasian M et al. Edmonson M. *Clinical Trials*. 1989;33(3):1-2.

Cite this article as: Singh RSS, Hisham MRM, Mohammad AT, Abbas SHF, Yusoff Y. An unusual case of primary peritoneal adenocarcinoma. *Int Surg J* 2020;7:3445-8.